Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.51
+2.6%		$5.20
$4.33
▼
$8.69
$2.37B0.385.32 million shs2.56 million shs
Cronos Group Inc. stock logo
CRON
Cronos Group
$3.14
-0.6%		$2.81
$2.28
▼
$3.43
$1.17B0.91.40 million shs1.03 million shs
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$9.32
+1.2%		C$9.60
C$5.66
▼
C$10.17
C$915.52M-0.19438498,691 shs122,188 shs
Cronos Group Inc stock logo
MJN
Cronos Group
C$12.15
-1.9%		C$12.15
C$1.58
▼
C$14.83
C$1.73BN/A2.07 million shs1.39 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
+2.52%+4.31%+33.16%+19.97%-9.34%
Cronos Group Inc. stock logo
CRON
Cronos Group
-0.63%+1.29%+14.60%+19.39%+19.85%
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
+1.19%-4.51%-4.12%+10.56%+46.77%
Cronos Group Inc stock logo
MJN
Cronos Group
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.51
+2.6%		$5.20
$4.33
▼
$8.69
$2.37B0.385.32 million shs2.56 million shs
Cronos Group Inc. stock logo
CRON
Cronos Group
$3.14
-0.6%		$2.81
$2.28
▼
$3.43
$1.17B0.91.40 million shs1.03 million shs
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$9.32
+1.2%		C$9.60
C$5.66
▼
C$10.17
C$915.52M-0.19438498,691 shs122,188 shs
Cronos Group Inc stock logo
MJN
Cronos Group
C$12.15
-1.9%		C$12.15
C$1.58
▼
C$14.83
C$1.73BN/A2.07 million shs1.39 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
+2.52%+4.31%+33.16%+19.97%-9.34%
Cronos Group Inc. stock logo
CRON
Cronos Group
-0.63%+1.29%+14.60%+19.39%+19.85%
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
+1.19%-4.51%-4.12%+10.56%+46.77%
Cronos Group Inc stock logo
MJN
Cronos Group
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.71
Reduce$8.0022.98% Upside
Cronos Group Inc. stock logo
CRON
Cronos Group
2.40
Hold$2.30-26.75% Downside
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
3.00
BuyC$9.501.93% Upside
Cronos Group Inc stock logo
MJN
Cronos Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GUD, BHC, MJN, and CRON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
Cronos Group Inc. stock logo
CRON
Cronos Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C+)
7/31/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
7/24/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/22/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
5/29/2026
Cronos Group Inc. stock logo
CRON
Cronos Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$10.85B0.22$7.48 per share0.87($2.14) per share-3.04
Cronos Group Inc. stock logo
CRON
Cronos Group
$179.09M6.50$0.01 per share252.06$3.01 per share1.04
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$547.31M1.67C$2.42 per share3.85C$8.13 per share1.15
Cronos Group Inc stock logo
MJN
Cronos Group
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$157M-$2.96N/A1.65N/A-10.12%-561.95%6.31%10/28/2026 (Estimated)
Cronos Group Inc. stock logo
CRON
Cronos Group
-$9.45M$0.2015.70N/AN/A39.08%4.85%4.62%N/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
-C$30.73MC$0.1562.13N/A2.72%1.91%0.51%N/A
Cronos Group Inc stock logo
MJN
Cronos Group
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest GUD, BHC, MJN, and CRON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Cronos Group Inc. stock logo
CRON
Cronos Group
$0.01$0.09+$0.08$0.09$44.20 million$53.01 million
8/6/2026Q2 2026
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/A-C$0.03N/A-C$0.03N/AC$143.97 million
7/29/2026Q2 2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.96$1.26+$0.30$0.68$2.59 billion$2.83 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/AN/AN/AN/AN/A
Cronos Group Inc stock logo
MJN
Cronos Group
C$1.6513.58%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
54.68
1.44
1.08
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
16.18
15.25
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
4.29
2.28
1.79
Cronos Group Inc stock logo
MJN
Cronos Group
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
22.77%
Cronos Group Inc stock logo
MJN
Cronos Group
N/A

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20.67%
Cronos Group Inc. stock logo
CRON
Cronos Group
7.80%
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
45.62%
Cronos Group Inc stock logo
MJN
Cronos Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,300374.13 million296.80 millionOptionable
Cronos Group Inc. stock logo
CRON
Cronos Group
450370.73 million341.81 millionOptionable
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
72598.23 millionN/ANot Optionable
Cronos Group Inc stock logo
MJN
Cronos Group
7,600142.65 millionN/ANot Optionable

Recent News About These Companies

Cronos Group (CVE:MJN) Share Price Passes Below 50 Day Moving Average - Here's What Happened
August 12 at 4:05 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30956820
Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles
July 21, 2026  |  financialpost.comF
Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
July 16, 2026  |  financialpost.comF
Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada
June 30, 2026  |  financialpost.comF
Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders
June 22, 2026  |  financialpost.comF
Cronos Announces Extension of Share Repurchase Program to the Toronto Stock Exchange
June 16, 2026  |  financialpost.comF
Spinach® is the Number One Vape Brand in Canada
June 11, 2026  |  financialpost.comF
Cronos Group Inc. (CRON) Stock Falls on Q1 2026 Earnings
May 11, 2026  |  quiverquant.comQ
Cronos Expands Pre-Roll Portfolio with Spinach STIX®
May 6, 2026  |  financialpost.comF
Cronos Group Inc. to Hold Virtual 2026 Annual Meeting of Shareholders
April 29, 2026  |  financialpost.comF
Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026
April 20, 2026  |  financialpost.comF
Cronos Group Inc. (CRON) Earns Buy Rating and C$4.50 PT on Scalable Model
March 3, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/cronos-group-inc-cron-earns-buy-rating-and-c4-50-pt-on-scalable-model-1708301/
Canaccord is Bullish on Cronos Group Inc. (CRON)
February 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/canaccord-bullish-cronos-group-inc-050625468.html
Canaccord is Bullish on Cronos Group Inc. (CRON)
February 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/canaccord-is-bullish-on-cronos-group-inc-cron-1696489/
Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026
February 12, 2026  |  financialpost.comF
Bernstein Reiterates Hold on Cronos Group Inc. (CRON) as Cash-Rich Balance Sheet Stands Out
January 25, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/bernstein-reiterates-hold-on-cronos-group-inc-cron-as-cash-rich-balance-sheet-stands-out-1681084/
Cronos Group reports Q3 EPS 7c vs 2c last year
November 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/cronos-group-reports-q3-eps-7c-vs-2c-last-year/ar-AA1PVXAb
Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025
October 23, 2025  |  financialpost.comF
Cronos Group Releases 2025 Second Quarter Results
September 16, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/cronos-group-releases-2025-second-quarter-results-1610156/
Cronos Token Jumps to Multi-Year Highs After Trump Media Partnership
August 28, 2025  |  financefeeds.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.50 +0.17 (+2.60%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$6.49 -0.01 (-0.18%)
As of 08/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Cronos Group stock logo

Cronos Group NASDAQ:CRON

$3.14 -0.02 (-0.63%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$3.14 -0.01 (-0.16%)
As of 08/14/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Knight Therapeutics stock logo

Knight Therapeutics TSE:GUD

C$9.32 +0.11 (+1.19%)
As of 08/14/2026 04:00 PM Eastern

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.

Cronos Group stock logo

Cronos Group CVE:MJN

C$12.15 -0.23 (-1.86%)
As of 03/2/2018

Cronos Group Inc, formerly PharmaCan Capital Corp, is a Canada-based cannabis company. The Company operates two Licensed Producers (LPs) regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations (the ACMPR) and holds a portfolio of investments in other Licensed Producers and ACMPR applicants. Its LPs, Peace Naturals Project Inc. and In The Zone Produce Ltd., are collectively located on over 125 acres of agricultural land. It also holds equity positions in Licensed Producers Whistler Medical Marijuana, Hydropothecary and Abcann Medicinals. Whistler Medical Marijuana is licensed to produce and sell medical marijuana, as well as cultivate cannabis oil. Hydropothecary is licensed to produce medical marijuana. Abcann Medicinals also has license to produce medical marijuana. With interest in five Licensed Producers and two LP applicants, it is focused on building brand portfolio providing patients with personalized care.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas